| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2014121764 |
| Title |
2-Substituted-6-Biarylmethylamino-9-Cyclopentyl-9H-Purine Derivatives, Use Thereof As Medicaments, and Pharmaceutical Compositions. |
| Abstract |
This invention relates to novel 2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, showing activity as specific inhibitors of growth and angiogenesis of hepatocellular carcinoma. The invention further includes pharmaceutical compositions containing the 2-substituted-6-biarylmethylamino-9-cyclopentylpurines. |
| Applicant(s) |
Univerzita Palackeho V Olomouci et al |
| Representative Drug(s) |
D07DUX |
Drug Info
|
IC50 = nM range |
[1] |
| Patent ID |
WO2013156780 |
| Title |
Therapeutic Compounds. |
| Abstract |
The present invention relates to compounds of formula (I): wherein R1 is NH2 or NHMe; R2 is halo; and one of R3 or R4 is hydrogen and the other is selected from ...O2NH2, -SO2NHMe or ...O2NMe2, -SO2NHEt, or -SO2NEt2; or a pharmaceutically acceptable salt or solvate thereof. The compounds of formula (I) are inhibitors of protein kinases, especially cyclic dependent kinases (CDKs) such as CDK9. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which protein kinase/CDK activity is implicated. |
| Applicant(s) |
Changzhou Le Sun Pharmaceuticals Limited |
| Representative Drug(s) |
D01CJE |
Drug Info
|
Ki = single digit nM |
[1] |
| Patent ID |
WO2013149976 |
| Title |
Indole-Pyrimidine Derivatives and Their Therapeutic Uses. |
| Abstract |
The present invention relates to new indole-pyrimidine derivatives of Formula (I), a process for obtaining them, a pharmaceutical composition comprising said compounds and their use in the treatment of several disease including cognitive, neurodegenerative or neurological diseases or conditions, diabetes, inflammatory and autoimmune diseases and cardiovascular disorders. |
| Applicant(s) |
Noscira, Sa |
| Representative Drug(s) |
D0F7DS |
Drug Info
|
IC50 = 1.5 nM |
[1] |
| Patent ID |
WO2011069334 |
| Title |
Cdk5 Inhibitors and Therapeutic Uses Thereof. |
| Abstract |
Natural occurring inhibitors of cyclin-dependent protein kinase 5 (Cdk5), isolated from the root of Rhodiola rosea are structurally different from the known Cdk inhibitors. They show selectivity among different Cdks and efficacy to inhibit Cdk via a mixed-type of inhibition, which should lead to less toxicity and side-effects. They are useful in preventing and treating diseases and disorders associated with aberrant Cdk5 activities, such as acute and/or chronic pain, neuropathic pain, diabetes mellitus, cancer, neurodegenerative diseases and neuropathological disorders. |
| Applicant(s) |
The Hong Kong University of Science and Technology |
| Representative Drug(s) |
D0KP8N |
Drug Info
|
IC50 = 3200 nM |
[1] |
| Patent ID |
WO2010103486 |
| Title |
Pyrazolo[1,5-A]-1,3,5-Triazine Derivatives, Preparation Thereof, and Therapeutic Use Thereof. |
| Abstract |
The present invention relates to a compound of the following formula (I), where R1 is a (C1-C6)alkyl group or a (C3-C6)cycloalkyl group; R2 and R3 are, independently, a (C1-C6)alkyl group, a (C3-C6)cycloalkyl group, a (C1-C6)alkenyl group, a (C1-C6)fluoroalkyl group, a (C1-C3)fluoroalkoxy group, or a (C1-C6)alkoxy(C1-C6)alkyl group substituted (i) by one to three hydroxyl groups or (ii) by an NRaRb, or R2 is a pyrrolidinylmethyl group substituted by one to three hydroxyl groups, assuming that R9 can be a hydrogen atom, or alternatively R2 and R3 are a heterocyclic compound with the nitrogen atom thereof; X and Y are, independently, a phenyl group or heteroaryl group, said heteroaryl and phenyl groups being substitutable, said heteroaryl group being selected from among a thienyl group, a pyridyl group, a pyrimidinyl group, a thiazolyl group, a pyrrolyl group, and furanyl group, as well as to the pharmaceutically acceptable salts thereof. The present invention also relates to the composition containing same, as well as to the therapeutic use thereof. |
| Applicant(s) |
Center Nat Rech Scient |
| Representative Drug(s) |
D0NB7Y |
Drug Info
|
IC50 = 14 nM |
[1] |
| Intellectual Property Office in India (IP India) |
| Patent ID |
INKO201101289 |
| Title |
Preparation of Naphthyridine and Isoquinoline Derivatives As Cdk Inhibitors. |
| Representative Drug(s) |
D08WJG |
Drug Info
|
IC50 = 4 nM |
[1] |
| French National Institute of Industrial Property (FINPI) |
| Patent ID |
FR2943058 |
| Title |
Preparation of Pyrazolo[1,5-A]-1,3,5-Triazine Derivatives As Inhibitors of Cyclin-Dependent Kinases, Casein Kinase 1 and Dyrk1A Kinase for Treating B-Cell Chronic Lymphoid Leukemia. |
| Representative Drug(s) |
D0NB7Y |
Drug Info
|
IC50 = 14 nM |
[1] |
